PATENT CLAIM ANALYSIS

Application Number: 15899061
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "210180"]

Abstract:
A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.

Claim (Index 18):
A combination product comprising:\n (A) compound as claimed in  claim 1 , or a pharmaceutically acceptable salt thereof; and (B) one or more other therapeutic agent(s) that is/are useful in the treatment of a disease, wherein each one of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and wherein the treatment does not comprise prevention or prophylaxis; wherein the disease is selected from the group consisting of soft tissue cancers selected from the group consisting of sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; lung cancers/diseases selected from the group consisting of bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma; gastrointestinal cancers/diseases selected from the group consisting of cancers of the esophagus, stomach, pancreas, small bowel, and large bowel; genitourinary tract cancers/diseases selected from the group consisting of cancers of the kidney, bladder and urethra, prostate, and testis; liver cancers/diseases selected from the group consisting of hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma; bone cancers/diseases selected from the group consisting of osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors; nervous system cancers/diseases selected from the group consisting of cancer of the skull, meninges, brain, and spinal cord; gynecological cancers/diseases selected from the group consisting of uterus, cervix, ovaries, vulva, and vagina; hematologic cancers; skin cancers/diseases selected from the group consisting of malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids; adrenal glands cancers/diseases, neuroblastoma, neurofibromatosis, head and neck cancers; and breast cancers.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 88.0
- Lexical Diversity: 1.18519
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14647400', '15447818', '15315461', '15315478', '11123755']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7767787052628076
- 35 USC 102 Novelty (BERT): 0.607310761719089
- Combined Prediction Score: 0.7598319109084357
- Mean Citation Score: 440.228286
- Max Citation Score: 523.1518
- Similarity Product: 493.6411734959482

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test